Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Talaris Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. Reiterates Buy on Talaris Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Talaris Therapeutics (NASDAQ:TALS) with a Buy and maintains $12 price target.

byBenzinga Newsdesk

January 30, 2023

1 minute read

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Talaris Therapeutics (NASDAQ:TALS) with a Buy and maintains $12 price target.

How Apogee Registers 10% Sales Growth In Q3: Architectural Framing Systems, Among Other Segments

By Anusuya Lahiri

December 22, 1:54 PM

Apogee Enterprises Inc (NASDAQ: APOG) reported third-quarter FY23 sales growth of 10.1% year-over-year to $367.8 million, beating the consensus of $363.4…

APOG

Barclays Maintains Underweight on Edgewell Personal Care, Raises Price Target to $38

By Benzinga Newsdesk

February 10, 10:02 AM

Barclays analyst Lauren Lieberman maintains Edgewell Personal Care (NYSE:EPC) with a Underweight and raises the price target from $37 to $38.

EPC

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

By Avi Kapoor

June 3, 7:41 AM

The Dow Jones index closed higher by around 575 points on Friday. When insiders purchase or sell shares,…

FRTX

Inspirato Q4 EPS $(0.11) Beats $(0.15) Estimate, Sales $86.63M Beat $80.77M Estimate

By Michael Horton

March 15, 5:06 PM

Inspirato (NASDAQ:ISPO) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 97.52 percent increase over losses of $(4.43) per share from the

ISPO

HC Wainwright & Co. Reiterates Buy on Talaris Therapeutics, Maintains $12 Price Target

Related Posts

How Apogee Registers 10% Sales Growth In Q3: Architectural Framing Systems, Among Other Segments

Barclays Maintains Underweight on Edgewell Personal Care, Raises Price Target to $38

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

Inspirato Q4 EPS $(0.11) Beats $(0.15) Estimate, Sales $86.63M Beat $80.77M Estimate